Financial Data and Key Metrics Changes - Total revenues for 2025 were $61.9 million, a 10% increase from $56.1 million in 2024, driven by the successful launch of EMROSI [17] - Gross margins improved to 66.2% in 2025 from 62.8% in 2024, reflecting a favorable product mix and lower inventory costs [17] - The company reported a GAAP net loss of $11.4 million, or $0.47 per share, compared to a loss of $14.7 million, or $0.72 per share in 2024 [18] - Adjusted EBITDA was positive at $2.9 million for 2025, up from $800,000 in 2024, indicating progress towards sustainable profitability [18] Business Line Data and Key Metrics Changes - EMROSI achieved $14.7 million in net sales during the three quarters it was available in 2025, with approximately 53,000 prescriptions written [5][7] - The total prescription volume for EMROSI grew nearly 50% sequentially in Q4 compared to Q3 [8] - The company ended 2025 with approximately 3,500 unique prescribers for EMROSI, surpassing its initial goal of 3,200 [9] Market Data and Key Metrics Changes - Approximately 100 million commercial covered lives have access to EMROSI, with contracts in place with two of the top three group purchasing organizations in the U.S. [10] - The company anticipates contracting with the third major GPO by late Q1 or early Q2 of 2026 [10] Company Strategy and Development Direction - The company aims to improve profitability and expand the commercial footprint of EMROSI while launching one or two additional dermatology products in 2026 [19][25] - Focus on building positive physician and patient experiences with EMROSI to drive prescription demand and improve reimbursement rates [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued sales growth and profitability, expecting to remain adjusted EBITDA positive in 2026 [7] - The company anticipates improved reimbursement rates and reduced reliance on co-pay bridging programs as coverage expands [11] - Management highlighted the importance of clinical data and publications in supporting EMROSI's market adoption and reimbursement evaluations [12][14] Other Important Information - The company ended 2025 with a cash position of approximately $24 million, up from $20.3 million at the end of 2024 [18] - Working capital at year-end was $29.4 million, an increase of $16.4 million from the previous year [19] Q&A Session Summary Question: Insights on EMROSI prescriptions trends for Q1 - Management noted that Q1 typically sees a slowdown due to insurance deductible resets and severe weather but expects Q1 prescriptions to surpass Q4 numbers [28][29] Question: Expectations for sequential growth in Q2 - Management indicated that momentum is building and expects Q2 to be stronger than Q1, with a run rate of over 126,000 prescriptions annually [30][46] Question: Clarification on revenue per script and gross-to-net expectations - Management explained that Q4's lower revenue per script was due to reimbursement mix and expects improvements in gross-to-net as reimbursement progresses [32][35][58] Question: Commentary on accounts receivable increase in Q4 - Management confirmed that most of the accounts receivable has been collected and attributed the increase to timing [66] Question: Future gross margins outlook as EMROSI gains coverage - Management expressed optimism for improved margins as EMROSI and other high-margin products become a larger part of the revenue mix [67]

Core Insights - Journey Medical Corporation presented efficacy data for DFD-29 (Emrosi) at the 2025 Fall Clinical Dermatology Conference, demonstrating its superiority over both placebo and Oracea in treating inflammatory lesions of rosacea [1][2][3] Company Overview - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on marketing FDA-approved prescription products for dermatological conditions, currently marketing eight branded drugs [11] Clinical Trial Results - In the Phase 3 trials, 62.7% of subjects treated with DFD-29 achieved IGA treatment success, compared to 39.0% for Oracea and 28.2% for placebo, with all comparisons showing statistical significance (p<0.001) [3][4][6] - The mean reduction in inflammatory lesions for DFD-29 was 19.2, compared to 14.8 for Oracea and 11.3 for placebo, also statistically significant (p<0.001) [3][4][6] Market Position - The results from the Phase 3 trials reinforce Emrosi's efficacy and safety profile, positioning it as a significant treatment option in the growing dermatology market [2][6] - The company aims to expand Emrosi's reach, believing it has the potential to become the standard of care for rosacea [2]